Literature DB >> 27385269

Is afatinib a treatment option for brain metastases in patients with EGFR mutation-positive non-small cell lung cancer?

Satomi Watanabe1, Hidetoshi Hayashi1, Kazuhiko Nakagawa1.   

Abstract

Entities:  

Year:  2016        PMID： 27385269      PMCID： PMC4916360          DOI： 10.21037/atm.2016.05.48

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  23 in total

1.  Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma.

Authors:  T Iuchi; M Shingyoji; T Sakaida; K Hatano; O Nagano; M Itakura; H Kageyama; S Yokoi; Y Hasegawa; K Kawasaki; T Iizasa
Journal:  Lung Cancer       Date:  2013-08-28       Impact factor: 5.705

2.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors:  Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

3.  Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

Authors:  Masahiro Fukuoka; Yi-Long Wu; Sumitra Thongprasert; Patrapim Sunpaweravong; Swan-Swan Leong; Virote Sriuranpong; Tsu-Yi Chao; Kazuhiko Nakagawa; Da-Tong Chu; Nagahiro Saijo; Emma L Duffield; Yuri Rukazenkov; Georgina Speake; Haiyi Jiang; Alison A Armour; Ka-Fai To; James Chih-Hsin Yang; Tony S K Mok
Journal:  J Clin Oncol       Date:  2011-06-13       Impact factor: 44.544

4.  Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.

Authors:  R Porta; J M Sánchez-Torres; L Paz-Ares; B Massutí; N Reguart; C Mayo; P Lianes; C Queralt; V Guillem; P Salinas; S Catot; D Isla; A Pradas; A Gúrpide; J de Castro; E Polo; T Puig; M Tarón; R Colomer; R Rosell
Journal:  Eur Respir J       Date:  2010-07-01       Impact factor: 16.671

5.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

6.  Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System.

Authors:  Jill S Barnholtz-Sloan; Andrew E Sloan; Faith G Davis; Fawn D Vigneau; Ping Lai; Raymond E Sawaya
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

7.  Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non-Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI.

Authors:  Akito Hata; Nobuyuki Katakami; Hiroshige Yoshioka; Reiko Kaji; Katsuhiro Masago; Shiro Fujita; Yukihiro Imai; Akihiro Nishiyama; Tadashi Ishida; Yoshihiro Nishimura; Yasushi Yatabe
Journal:  J Thorac Oncol       Date:  2015-11       Impact factor: 15.609

8.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Authors:  Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

9.  Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: distinguishing influence of exon 19 deletion on radiographic features.

Authors:  Akimasa Sekine; Terufumi Kato; Eri Hagiwara; Takeshi Shinohara; Takanobu Komagata; Tae Iwasawa; Hiroaki Satoh; Katsumi Tamura; Tomotaka Kasamatsu; Kenji Hayashihara; Takefumi Saito; Hiroshi Takahashi; Takashi Ogura
Journal:  Lung Cancer       Date:  2012-02-13       Impact factor: 5.705

10.  Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy.

Authors:  Yin-Duo Zeng; Hai Liao; Tao Qin; Li Zhang; Wei-Dong Wei; Jian-Zhong Liang; Fei Xu; Xiao-Xiao Dinglin; Shu-Xiang Ma; Li-Kun Chen
Journal:  Oncotarget       Date:  2015-04-10
View more
  5 in total

1.  The evolving first-line treatment of advanced non-small cell lung cancer harbouring epidermal growth factor receptor mutations.

Authors:  Lore Decoster; Philippe Giron; Sacha Mignon; Jacques De Grève
Journal:  Transl Lung Cancer Res       Date:  2018-04

2.  Current evidence in support of the second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor alectinib for the treatment of non-small cell lung cancer positive for ALK translocation.

Authors:  Hidetoshi Hayashi; Kazuhiko Nakagawa
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

3.  Overcoming the acquired resistance to gefitinib in lung cancer brain metastasis in vitro and in vivo.

Authors:  Zhongwei Liu; Neal Shah; Kent L Marshall; Samuel A Sprowls; Pushkar Saralkar; Afroz Mohammad; Kathryn E Blethen; Tasneem A Arsiwala; Ross Fladeland; Paul R Lockman; Weimin Gao
Journal:  Arch Toxicol       Date:  2021-08-28       Impact factor: 6.168

4.  The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer.

Authors:  Hyun Ae Jung; Sook Young Woo; Se-Hoon Lee; Jin Seok Ahn; Myung-Ju Ahn; Keunchil Park; Jong-Mu Sun
Journal:  Transl Lung Cancer Res       Date:  2020-10

Review 5.  Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience.

Authors:  Biagio Ricciuti; Sara Baglivo; Andrea De Giglio; Rita Chiari
Journal:  Ther Adv Respir Dis       Date:  2018 Jan-Dec       Impact factor: 4.031
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.